Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.
Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.
复制标题
DOI：
10.1016/j.hemonc.2016.08.005
复制
发表时间：
2017-03-01
期刊：
影响因子：
--
通讯作者：
Shakeri, Sepideh
中科院分区：
文献类型：
--
作者：
Ayatollahi, Hossein;Shajiei, Arezoo;Shakeri, Sepideh
目的/背景：急性髓性白血病（AML）被定义为白血病母细胞在骨髓中的繁殖。染色体异常形成不同的亚群，具有共同的临床特征和结果。t(8;21)（q22;q22）和inv(16)（p13;q22）构成核心结合因子- aml （CBF-AML）。12.8-46.1%的成人CBF白血病患者发生c-kit突变激活。这些突变发生在20-25%的t（8;21）和30%的v（16）病例中。方法：在本系统综述中，我们检索了不同的数据库，包括PubMed、Scopus和Embase。选取的文章根据本研究的纳入标准进行测量，并在标题或摘要方面进行初步比较。最后，检索与本综述主题相关的文章全文。22篇符合纳入标准的文章入选本综述。结果：在本研究中，c-kit突变与t（8;21）和inv（16）的AML患者预后不良相关。此外，这些突变对携带inv的AML患者的预后效果优于携带t的患者（8;21）。结论：根据本研究结果，c-kit突变对成人CBF-AML的复发和白细胞增加具有强烈的有害影响。然而，这些突变对患者没有显著的预后影响。
OBJECTIVE/BACKGROUND: Acute myeloid leukemia (AML) is defined as leukemic blast reproduction in bone marrow. Chromosomal abnormalities form different subgroups with joint clinical specifications and results. t(8;21)(q22;q22) and inv(16)(p13;q22) form core binding factor-AML (CBF-AML). c-kit mutation activation occurs in 12.8-46.1% of adults with CBF leukemia. These mutations occur in 20-25% of t(8;21) and 30% of inv(16) cases.METHODS: In this systematic review, we searched different databases, including PubMed, Scopus, and Embase. Selected articles were measured based on the inclusion criteria of this study and initially compared in terms of titles or abstracts. Finally, articles relevant to the subject of this review were retrieved in full text. Twenty-two articles matched the inclusion criteria and were selected for this review.RESULTS: In this study, c-kit mutations were associated with poor prognosis in AML patients with t(8;21) and inv(16). In addition, these mutations had better prognostic effects on AML patients with inv(16) compared with those with t(8;21).CONCLUSION: According to the results of this study, c-kit mutations have intense, harmful effects on the relapse and white blood cell increase in CBF-AML adults. However, these mutations have no significant prognostic effects on patients.